Skip to main content

ICE MAKE top line grows 53% to Rs 200cr in FY2022

 


Net profit rise 103 % to Rs 7.32 crore

BOD Recommends 12%Dividend for FY2022


Ice Make Refrigeration Limited (NSE: ICEMAKE),a leading supplier of innovative cooling solutions and manufacturer of 50 plus refrigeration equipments in India, has reported strong growth in financial performance for the fiscal year ended March 31, 2022.

Net profit rose 85.57% to Rs 5.53 crore in the quarter ended March 2022 as against Rs 2.98 crore during the previous quarter ended March 2021. Sales rose 42.94% to Rs 76.90 crore in the quarter ended March 2022 as against Rs 53.80 crore during the previous quarter ended March 2021.

For the full year,net profit jumped 102.77% to Rs 7.32 crore in the year ended March 2022 as against Rs 3.61 crore during the previous year ended March 2021. Top line grew 53.06% to Rs 206.10 crore in the year ended March 2022 as against Rs 134.65 crore during the previous year ended March 2021.

 Mr. Chandrakant Patel, CMD, Ice Make Refrigeration Limited saidIt gives me immense pleasure to announce that we have achieved an important financial milestone as the Company has surpassed Rs 200 cr annual turnover this year on account of improved business environment driven by the strong growth in ammonia vertical, E-commerce business, export, food processing sector and there were multifold increase in solar cold room orders. Net profit registers strong 103% growth on a year on year basis and led by sharp jump in revenue. Robust demand from the end markets fuelled overall growth and profitability.  Despite cost pressure  where we faced challenges  like raw material prices volatility, transport price hike, however, to mitigate challenges, the Company took steps like increase in selling prices couple of time in FY 21-22.

Going forward, despite global economy going through inflationary pressures, the outlook for our business is looking pretty decent.  We have strong current order book and leads available for accelerated growth along with various product expansions plans like the recent unveiling of SoloPreriFresh brand” he said

Key Highlights -Consolidated Financial Performance: Q4FY22

       During Q4FY22 revenue from operations saw a robust 42.94% year-on-year growth. Compared to Q3FY22, revenue was up by 57.4%

       Consolidated revenue in Q4FY22 stood at Rs 76.90 crore compared to Rs 53.80 crore in Q4FY21.

       Inflationary pressure and higher global commodity prices led to increase in input prices raw material cost increase marginally as percent of revenue 72.95% as against 71.59% in Q4FY21.

       Despite higher cost, EBITDA jumped by 58.6% on a year on year basis as a result of higher revenue, better realizations and cost control.

       In Q4FY22 EBITDA margins increased by 123 basis points to 11.6% as against 10.3% in Q4FY21.

       Finance cost was up by 70.1% on a year on year basis. It stood 0.70% of total revenue in Q4FY22 as compared to 0.59% in Q4FY21. Company’s interest coverage ratio is till quite healthy 14.82 times.

       Net profit during Q4FY22 stood at Rs 5.53 crore as against Rs 2.98 crore in Q4FY21 registering strong 86% year on year growth. Moreover compared to Q3FY22, net profit made 335.4% or over three fold gain. 

Key Highlights -Consolidated Financial Performance: FY22 (Annual)

       Net profit register strong 103% growth on a year on year basis and led by sharp jump in revenue. Robust demand from the end markets fuelled overall growth and profitability.

       In fiscal year 2022, the company posted a strong 53.1% year on year growth in revenue to Rs 206.1 crore as against Rs 134.6 crore revenue in the fiscal 2021.

       Increase in input cost and commodity prices led to marginal jump in raw material cost. Efforts to control material cost and other fixed costs resulted in maintaining good profitability. During fiscal 2022 cost of material consumed were up by 4.36% on a year on year basis.

       Despite input price pressure company maintained good profitability. During the year EBITDA grew by 31.6% on a year on year basis to Rs 15.2 crore. EBITDA margins in this period stood at 7.3% compared to 8.5% in fiscal 2021.

       Finance cost fell by 9% year on year basis to Rs 1.73 crore. Due to higher profitability and scale interest coverage ratio has improved 6.67 times as against 3.77 times in fiscal 2021.

       The Board recommended a final dividend of Rs 1.2 (12%) per equity share of Rs 10 each for FY2022.

Comments

Popular posts from this blog

Smallcase Platform: 2025 Wealth Creation Strategies to Achieve Your Investment Goals

  By Dr. Vikas Gupta, CEO and Chief Investment Strategist, OmniScience Capital In the intricate world of finance, wealth creation is a universal aspiration among investors, though few truly attain it. With a plethora of investment products, philosophies, and strategies available, the challenge is identifying an approach that not only offers returns but also minimizes risk. At OmniScience Capital, we believe the key to successful wealth creation lies in a scientific and disciplined investment strategy. Our unique offerings, rooted in the principles of Scientific Investing, are designed to help you achieve your financial goals with confidence. Pioneering Global Investing and Outperforming on Smallcase Platform OmniScience Capital, a global investment management firm specializing in global and Indian equities, is a pioneer in global investing and growth vectors such as Defense and Digital Transformation. Our strategies have consistently identified and capitalized on growth vectors tha...

Country Delight Launches NMR-Tested Honey: The Gold Standard of Purity

  Country Delight continues strengthening its promise of delivering the best purity and quality by launching 100% Pure Farm Honey (NMR Tested) Country Delight, a trusted name in premium and natural essentials, has announced the launch of 100% Pure Farm Honey (NMR Tested). Country Delight’s Farm Honey is Nuclear Magnetic Resonance (NMR) tested by a certified lab in Germany, making it one of the most authentic and reliable kitchen ingredients available to Indian homes. It also undergoes rigorous testing on 36 quality parameters as per FSSAI standards, including physicochemical, antibiotic and microbial, to rule out the presence of added sugars. Honey is not just a natural sweetener; it is increasingly valued for its functional benefits. With Country Delight's NMR-tested honey, consumers can enjoy a product that supports wellness through its natural composition, which is rich in antioxidants and phytonutrients and offers advantages over refined sugars.  Adulteration with cheaper ...

Prachay Capital’s Public Issue of Secured NCDs Fully Subscribed at 113.36%

Prachay Capital Limited, an RBI-registered Non-Banking Financial Company – Investment and Credit Company (NBFC-ICC), has successfully closed its public issue of Secured, Rated, Redeemable Non-Convertible Debentures (NCDs) at 113.36% subscription, according to exchange data. The issue, which opened on February 28, 2025, on the Bombay Stock Exchange (BSE), aimed to raise Rs 50 crore (excluding the greenshoe option) and closed on March 13, 2025. With a BSE listing, this issue was open for subscription to retail investors, high-net-worth individuals (HNIs), institutional investors, and corporates. The maiden NCDs issue is scheduled to list on 24 March 2025.  Rated BBB-/Stable by CRISIL, these NCDs offer investors a 13% per annum return with monthly interest payouts, making them an attractive fixed-income opportunity. The proceeds will be deployed as per the company’s stated fund allocation plan. Fund Utilization: Minimum 75% for the purpose of onward lending, investments in current and...